Studies on effectiveness of new HCV therapies presented at 76th ACG meeting
Post on: 2011-11-02 By: admin
Studies reporting on the effectiveness of new therapies for chronic Hepatitis C virus are among the clinical science presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where investigators also presented findings from an age-based risk assessment and screening intervention for Hepatitis C among Baby Boomers, patients aged 50-65, who saw a gastroenterologist for routine colon cancer screening.With the recent introduction of new direct acting anti-viral therapies, physicians now have more options for treatment of chronic hepatitis, a chronic viral liver disease that infects more than 4 million Americans. Several studies of the new drug telaprevir in combination with the standard of care (pegylated interferon and ribavirin) looked at the drug's effectiveness among populations of patients who, because of race or failure of previous treatment, are considered hard-to-treat.Treatment Effect and Resistance Profiles were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination RegimenDr. Andrew Muir of Duke University Medical Center and a group of investigators in a large multi-center trial evaluated data on safety and efficacy from two Phase 3 trials (ADVANCE and ILLUMINATE) of the direct acting anti-viral drug telaprevir in combination with the standard of care (peylated interferon and ribavirin) for the treatment of chronic hepatitis C.In African Americans, a group for whom the need for effective therapies is particularly urgent, a combination treatment of telaprevir with pegylated interferon and ribavirin provided a substantial improvement in Sustained Viral Response (SVR) - compared to the standard treatment. SVR means that the hepatitis C virus level is undetectable 6 months after stopping therapy and signifies the patient has been cured of the infection. Patients in the Black/African American group had an SVR rate of 61% when treated with the telaprevir combination compared to 25% with the previous standard of care. Response-guided Telaprevir Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Pegylated Interferon/RibavirinDr. Muir was also involved in an analysis of results of the Phase 2 (PROVE3) and Phase 3 (ADVANCE, ILLUMIATE and REALIZE) telaprevir studies of patients who relapsed to a prior treatment with the standard of care (pegylated interferon and ribavirin.) Prior relapsers are eligible for shortened duration with the telaprevir combination, and this analysis provides some of the rationale for the response-guided therapy approach for these patients. The investigators looked at patients with prior relapse with peginterferon and ribavirin and then reported their response when given the telaprevir combination. The study reported SVR and relapse rates and studied the effect of the varying treatment durations in the different studies. They compared these results with the outcomes of those who had never been treated for Hepatitis C in the past.
Related postsVertex initiates INCIVEK combination Phase 3b study for hepatitis CVertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCIS...Mayo Clinic develops new screening procedure for Lynch syndrome detectionMayo Clinic has developed a screening procedure that could dramatically increase testing for Lynch s...Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCVVertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as p...ECRI Institute introduces CT Radiation Dose Safety Review service to reduce risk of excessive radiationKeeping radiation dose in check is a top safety concern for today's hospitals, particularly in compu...Signaling pathway inhibition enhances autologous bone marrow transplant: ResearchIdentification of a molecular communications pathway that influences the mobilization of hematopoiet...Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programsRegulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic progr...Idera Pharmaceuticals announces financial results for the third quarter of 2009Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months e...GENova Biotherapeutics and Korean university sign strategic partnership agreementGENova Biotherapeutics Inc. ("GENova") today announced that it has signed a LOI for a strategic part...Medtronic's COPE-HCV clinical study commencesMedtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntin...Guidelines for von Willebrand disease diagnosis and managementThe National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health today iss...Bovine protein called lactoferrin aids in treatment of gastrointestinal disorderRecent evidence suggests that therapy currently used to treat Helicobacter pylori (H. pylori) infect...Quality indicators for gastrointestinal endoscopic proceduresDefining measurements and identifying quality standards in the delivery of colonoscopic care is a ma...Kids learn about STD's when they are getting diagnosed with themMost sexually active teenage girls know relatively little about sexually transmitted diseases (STDs)...Combination treatment may help type 2 diabetes patientsNew research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Sci...
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Cancel reply to comment
Bolivarian Republic of Venezuela
Bolivia
Bosnia and Herzegovina
Islamic Republic of Pakistan
People's Republic of China
Principality of Monaco
Republic of the Philippines
Serbia and Montenegro (Former)
Notify me when new comments are added
Medical / Health Products
Medical / Health Services
Other AZoNetwork Websites
News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Article original from: http://www.news-medical.net/news/20111101/Studies-on-effectiveness-of-new-HCV-therapies-presented-at-76th-ACG-meeting.aspx
